"Blood Component Removal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any procedure in which blood is withdrawn from a donor, a portion is separated and retained and the remainder is returned to the donor.
| Descriptor ID |
D001781
|
| MeSH Number(s) |
E02.120
|
| Concept/Terms |
Blood Component Removal- Blood Component Removal
- Blood Component Removals
- Component Removal, Blood
- Component Removals, Blood
- Removal, Blood Component
- Removals, Blood Component
- Pheresis
- Phereses
- Apheresis
- Aphereses
|
Below are MeSH descriptors whose meaning is more general than "Blood Component Removal".
Below are MeSH descriptors whose meaning is more specific than "Blood Component Removal".
This graph shows the total number of publications written about "Blood Component Removal" by people in this website by year, and whether "Blood Component Removal" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 1 | 2 |
| 2014 | 1 | 0 | 1 |
| 2021 | 1 | 1 | 2 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Blood Component Removal" by people in Profiles.
-
Low-density lipoprotein apheresis for recurrent focal segmental glomerulosclerosis post renal transplant in pediatric patients. J Clin Apher. 2022 Aug; 37(4):411-414.
-
Liposorber? LA-15 system for LDL apheresis in resistant nephrotic syndrome patients. Pediatr Nephrol. 2022 03; 37(3):585-592.
-
A simplified CD34+ based preharvest prediction tool for HPC(A) collection. Transfusion. 2021 05; 61(5):1525-1532.
-
Similar dynamics of intraapheresis autologous CD34+ recruitment and collection efficiency in patients undergoing mobilization with or without plerixafor. Transfusion. 2014 Dec; 54(12):3131-7.
-
Incidence and clinical significance of cardiac biomarker elevation during stem cell mobilization, apheresis, and intramyocardial delivery: an analysis from ACT34-CMI. Am Heart J. 2012 Nov; 164(5):689-697.e3.
-
Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis. Transfusion. 2012 Nov; 52(11):2375-81.
-
Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res. 2011 Aug 05; 109(4):428-36.
-
Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant. 2011 Jan; 46(1):64-9.
-
CD34+ immune suppressive cells in the peripheral blood of patients with head and neck cancer. Ann Otol Rhinol Laryngol. 2000 Aug; 109(8 Pt 1):749-54.
-
Assessing the efficiency of leukoreduction of cellular blood components. Use of a simplified formalin-fixation and batch-counting method. Am J Clin Pathol. 1997 Jan; 107(1):111-3.